Accumark Labs

CERTIFICATE OF ANALYSIS

P²Collective

SAMPLE NAME: Retatrutide
SAMPLE CODE: GY7S-NK7Q
RECEIVED DATE: 11/02/2026
PUBLISHED DATE: 11/04/2026




DECLARED IDENTITY	Retatrutide
MATRIX TYPE:	PEPTIDE
SAMPLE NAME:	Retatrutide
SAMPLE SIZE:	20.0 mg
Nº LOT CODE:	P2-RT20-1026

23.917 mg
Total Quantity

99.921%
Total Blend Purity

Sample	Test	Specification	Result	Status
Retatrutide	IDENTITY	Retatrutide	Retatrutide	CONFORMS
Retatrutide	QUANTITY	As measured	23.917 mg	MEASURED
Retatrutide	PURITY	≥ 98 %	99.921%	CONFORMS

HPLC Chromatogram Report



RESULTS REVIEWED BY:
Anthony Burke PhD
Lab Manager
11/04/2026

RESULTS CERTIFIED BY:
Dr. Levi Fried MD
Lab Director
11/04/2026

ACCUMARKLABS.COM
GY7S-NK7Q
11/04/2026

Accumark Labs

CERTIFICATE OF ANALYSIS

P²Collective

SAMPLE NAME:	Retatrutide
SAMPLE CODE:	GY7S-NK7Q
RECEIVED DATE:	11/02/2026
PUBLISHED DATE:	11/04/2026

Endotoxin USP85 LAL

Basis: USP<85> Parenteral 350 EU/dose | Assumed 70 kg, whole vial per dose

Test	Specification (EU/vial)	Result (EU/vial)	LOQ (EU/vial)	Verdict
Endotoxin USP85 LAL	< 350	< 50	50	**Conforms**

Method: Endotoxin testing performed using Limulus Amebocyte Lysate assay in accordance with USP <85> under validated laboratory conditions. LOD 0.05 EU/mL.

Basis Endotoxin specification is set assuming the full contents of the vial are administered in one dose.
Reporting A result below 350 EU/vial means the USP<85> safe limit for a 70 kg adult will not be exceeded, regardless of how the vial is dosed.

RESULTS CERTIFIED BY:

Anthony Burke PhD
Lab Manager
11/04/2026

RESULTS CERTIFIED BY:

Dr. Levi Fried MD
Lab Director
11/04/2026

ACCUMARKLABS.COM
GY7S-NK7Q
11/04/2026